Specific cognitive deficits and differential domains of social functioning impairment in schizophrenia

Cohen, Alex S.; Forbes, Courtney Brynn; Mann, Monica; Blanchard, Jack J.

doi:10.1016/j.schres.2005.09.007

Cited by 70 publications

(45 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has broad-spectrum efficacy across nonclinical models of memory consolidation, inhibitory avoidance, social recognition memory, working memory, and sensory gating deficit, which are domains of cognition that are negatively affected in schizophrenia (8). Our previous studies in healthy volunteers, patients with schizophrenia, and patients with Alzheimer's disease indicated that ABT-126 was generally well tolerated at all dosages tested (up to 150 mg once daily).…”

mentioning

confidence: 97%

A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia

Haig¹,

Bain²,

Robieson³

et al. 2016

AJP

View full text Add to dashboard Cite

Objective: The authors sought to evaluate the efficacy and safety of ABT-126, a selective a7 nicotinic receptor partial agonist, in stable patients with schizophrenia.Method: A 12-week, double-blind, placebo-controlled, parallel-group phase 2 study was conducted in 22 centers in the United States. Clinically stable patients with schizophrenia were randomly assigned to receive once-daily dosing with 10 mg of ABT-126, 25 mg of ABT-126, or placebo. The primary efficacy measure was change from baseline to week 12 on the MATRICS Consensus Cognitive Battery (MCCB) composite score compared with placebo, tested by a one-sided t test. Secondary measures included MCCB domain scores and UCSD Performance-Based Skills Assessment total score, each tested by two-sided t tests.Results: A total of 207 subjects were randomized, of whom 165 (81%) completed the study. ABT-126 showed an improvement that fell short of significance on the MCCB composite score at week 12 (least squares mean difference from placebo, 1.3 and 1.5 for the 10 mg and 25 mg groups, respectively). A significant treatment-by-smoking status interaction was observed on the mean change from baseline to final MCCB composite score: nonsmokers (N=69) demonstrated a difference from placebo of 2.9 (SE=1.4) in the 10 mg group and 5.2 (SE=1.6) in the 25 mg group, whereas no differences were observed in smokers (N=113). Among the nonsmokers in the ABT-126 25 mg group (N=19), significant improvements compared with placebo occurred at final assessment for verbal learning (least squares mean difference=5.5, SE=1.9), working memory (least squares mean difference=5.4, SE=2.0), and attention/vigilance (least squares mean difference=8.7, SE=2.5). The most frequently reported adverse events for ABT-126 were dizziness, diarrhea, and fatigue (all ,8% incidence).Conclusions: ABT-126 demonstrated a procognitive effect in nonsmoking subjects, particularly in verbal learning, working memory, and attention.

show abstract

mentioning

confidence: 97%

A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia

Haig¹,

Bain²,

Robieson³

et al. 2016

AJP

View full text Add to dashboard Cite

show abstract

“…En este estudio se han utilizado dos medidas de evaluación de funcionamiento comunitario (una autoaplicada y otra heteroaplicada), sin embargo, no se evaluaron otras dimensiones del funcionamiento social como las habilidades sociales, la resolución de problemas sociales o el comportamiento en el entorno. Los resultados nos muestran que el reconocimiento de la emoción no predice el rendimiento general en las habilidades para la vida cotidiana pero sí hay evidencia de otros estudios en los que predice otras áreas del funcionamiento social como las habilidades sociales (Cohen, Forbes, Mann y Blanchard, 2006;Ihnen et al, 1998), el rendimiento en el trabajo (Kee et al, 2003) o las habilidades interpersonales (Pinkham y Penn, 2006;Poole et al, 2000).…”

Section: Discussionunclassified

Relaciones entre neurocognición, procesamiento emocional y funcionamiento social en la esquizofrenia

Jaramillo

Ruíz

Fuentes

2017

PSYE

View full text Add to dashboard Cite

RESUMEN:En la esquizofrenia se presentan una serie de déficits cognitivos que han hecho que la investigación y la práctica profesional actual se centren en el estudio de la neurocognición y la cognición social. Estos déficits tienen importantes implicaciones en el funcionamiento social. El objetivo del presente trabajo es analizar la relaciones entre neurocognición, cognición social, evaluada con tareas de reconocimiento de la emoción, y funcionamiento social. Sesenta personas con diagnóstico de esquizofrenia han formado la muestra y las áreas evaluadas han sido: funcionamiento ejecutivo y flexibilidad cognitiva, atención y vigilancia, memoria, velocidad de procesamiento, identificación y discriminación de emociones y funcionamiento comunitario. Los resultados indican que medidas de cognición básica correlacionan de forma significativa con el funcionamiento comunitario, mientras que medidas de reconocimiento de la emoción, específicamente la identificación de emociones faciales solo correlacionó de forma positiva con un área del funcionamiento comunitario, la de comunicación y contacto social. Palabras clave: esquizofrenia, procesamiento emocional, cognición social, neurocognición y funcionamiento social. Relationships between neurocognition, emotional processing and social functioning in schizophreniaABSTRACT: A series of cognitive deficits in schizophrenia have led to a focus on neuro-and social cognition in current research and professional practice. These deficits have significant implications for social functioning. The aim of the current study is to analyse the relationships between neurocognition, social cognition (evaluated via emotional recognition tasks) and social functioning. Sixty people diagnosed with schizophrenia made up the sample and the following areas were evaluated: executive functioning and cognitive flexibility, attention and vigilance, processing speed, emotion identification and discrimination and community functioning. results indicate that measures of basic cognition correlate significantly with communal functioning while measures of emotion recognition, especially those identifying facial emotions only correlate positively with one area of communal functioning, namely that of communication and social contact.

show abstract

“…The Global Assessment of Function scale, the Global Assessment Scale, and the Social Functioning Scale are the most frequently reported social functioning scales in the assessment of schizophrenia but the PSP is not often used (Burns & Patrick, 2007). These frequentlyused scales differ from the PSP in that they focus on the degree of social engagement, whereas the PSP measures the social competence domain of social functioning (Cohen, Forbes, Mann, & Blanchard, 2006). The PSP also differs from some of the frequently-used scales in that it is solely based on the appraisal of the assessor and not on self-report.…”

Section: Study Limitationsmentioning

confidence: 99%

Metacognition in Relation to Cognitive and Social Functioning in Schizophrenia

2015

Journal of European Psychology Students

View full text Add to dashboard Cite

The aim of the current study is to examine metacognitive functioning in people with schizophrenia, in the light of everyday functioning. More specifically, links with several cognitive domains (i.e., attention, executive functioning and processing speed) and social functioning are analyzed using linear regressions. Based on previous literature, a close relationship between social and cognitive functioning is expected, as well as a mediation effect of metacognition on this relationship. The present findings suggest however, that cognition, social functioning, and metacognition are not related. Therefore, the model in which metacognition mediates the relationship between cognitive and social functioning in people with schizophrenia does not hold.

show abstract

Specific cognitive deficits and differential domains of social functioning impairment in schizophrenia

Cited by 70 publications

References 44 publications

A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia

A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia

Relaciones entre neurocognición, procesamiento emocional y funcionamiento social en la esquizofrenia

Metacognition in Relation to Cognitive and Social Functioning in Schizophrenia

Contact Info

Product

Resources

About